Ironwood Pharma (IRWD) Misses Q3 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ironwood Pharmaceuticals Provides Third Quarter 2018 Investor Update
November 6, 2018 8:09 AM ESTLINZESS® (linaclotide) U.S. net sales increased 7% to $205 million in 3Q 2018 vs 3Q 2017
Ironwood revenue of $66 million in 3Q 2018, which includes a $30 million reduction due to LINZESS change in estimate as reported to Ironwood by Allergan
Received Fast Track Designation for praliciguat for potential treatment of HFpEF
On track to complete separation of Ironwood into two independent, publicly traded companies in first half 2019
CAMBRIDGE, Mass.--(BUSINESS WIRE)--... More
